bTMB Analytical Validation Working Group

Mark Sausen, PhD

Head of Technology Innovation

Personal Genome Diagnostics

Co-Chairs

Jonathan Baden, PhD

Executive Director, Head of Precision Medicine

Bristol Myers Squibb

Current Projects

Not determined.

Participating Organizations

AstraZeneca, Bristol Myers Squibb (BMS), Delfi Diagnostics, Guardant Health, Illumina, Labcorp, LGC SeraCare, Tempus

Past Deliverables

October 2025: Analytical Validation of Blood-Derived Tumor Mutation Burden (bTMB) Assays: A Joint Consensus Recommendation of the BLOODPAC bTMB Analytical Validation Working Group (manuscript in press)

Meetings

This working group meets on zoom for one hour on a bi-weekly basis.

Special workshops and sessions:

Not applicable at this time.